Summary
Circulating tumor DNA (ctDNA) can detect minimal residual disease (MRD) in early-stage lung cancer, predicting relapse. The TRACERx study showed ctDNA identified MRD earlier than standard imaging in patients who relapsed.
Area of Science:
- Oncology
- Molecular Diagnostics
Background:
- Minimal residual disease (MRD) is a key predictor of relapse in early-stage non-small cell lung cancer (NSCLC).
- Circulating tumor DNA (ctDNA) analysis offers a potential method for detecting MRD non-invasively.
Discussion:
- The TRACERx study investigated the utility of ctDNA for MRD detection in early-stage NSCLC.
- ctDNA assays demonstrated high sensitivity in identifying MRD post-treatment.
Key Insights:
- ctDNA negativity was confirmed in over 99% of patients.
- ctDNA detected MRD in relapsed patients prior to standard imaging detection, highlighting its prognostic value.
Outlook:
- ctDNA-guided MRD monitoring may improve early-stage NSCLC management.
- Further research can refine ctDNA assays for earlier and more accurate relapse prediction.
